Undislosed M4 PAM / Addex - LARVOL DELTA

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders (Businesswire) - "Lead program, M4 PAM for schizophrenia, advancing towards clinical studies...Neurosterix...launched today with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures."

Financing • CNS Disorders • Schizophrenia